We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 23.50 | 1.38% | 1,728.50 | 1,727.50 | 1,728.50 | 1,729.50 | 1,695.50 | 1,705.00 | 6,275,082 | 16:35:24 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.44 | 71.14B |
From May 2022 to May 2024
TIDMGSK
RNS Number : 6484L
GlaxoSmithKline PLC
16 May 2022
GSK plc
(the 'Company')
Change of name to GSK plc
The Company today confirms its name has changed from GlaxoSmithKline plc to GSK plc.
The Company announced the decision to change its name to GSK plc on 27 April 2022 together with its first quarter 2022 results. This change has now taken effect.
The London Stock Exchange and the New York Stock Exchange will reflect the change of name in due course.
Shareholders should note that their shareholdings will be unaffected by the change of name. Existing share certificates should be retained as they will remain valid for all purposes and no new share certificates will be issued.
The ISINs, SEDOLs, CUSIPs and ticker symbols of the Company's ordinary shares and ADS remain unchanged. The Company's Legal Entity Identifier (LEI) remains 5493000HZTVUYLO1D793.
V A Whyte
Company Secretary
16 May 2022
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
CANFLFVFEVIRLIF
(END) Dow Jones Newswires
May 16, 2022 09:00 ET (13:00 GMT)
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
